The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-019-02065-3
Abstract: PurposeOur main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel).Patients and methodsA prospective cohort of patients with stage… read more here.
Keywords: group; ovarian cancer; plus doxorubicin; cancer ... See more keywords
Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Oral oncology"
DOI: 10.1016/j.oraloncology.2017.03.017
Abstract: PURPOSE To compare the treatment outcomes and toxicity of both cisplatin and cisplatin plus 5FU chemotherapy in head and neck cancer patients who have received surgery, in addition to postoperative chemoradiotherapy. MATERIALS AND METHODS From… read more here.
Keywords: cisplatin; plus 5fu; patients received; cisplatin plus ... See more keywords
Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz436.005
Abstract: Abstract Background The optimal chemotherapy regimen to use with radiotherapy in stage III non–small cell lung cancer (NSCLC) is still unknown. This phase III comparative randomized trial was conducted to determine the optimal chemotherapy regimen… read more here.
Keywords: stage iii; cisplatin plus; oncology; plus etoposide ... See more keywords
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302
Sign Up to like & getrecommendations! Published in 2019 at "Oncology"
DOI: 10.1159/000501967
Abstract: Background: There has been no study so far on gemcitabine continuous maintenance therapy targeting only squamous non-small-cell lung cancer (NSCLC) patients. This study aimed to assess the efficacy and safety of cisplatin plus gemcitabine followed… read more here.
Keywords: gemcitabine; maintenance; maintenance gemcitabine; study ... See more keywords
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4503
Abstract: 4503 Background: Transurethral resection of bladder tumor (TURBT) plus systemic therapy has been known for decades to achieve durable bladder-intact survival in a subset of patients with MIBC but efforts to advance this paradigm have… read more here.
Keywords: cisplatin plus; cytology; bladder; ccr ... See more keywords
The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.197
Abstract: 197Background: JCOG1013, a phase III study comparing CS therapy with DCS therapy for AGC, failed to demonstrate the superiority of DCS to CS in overall survival (OS) (Yamada Y, Lancet GH 2019). Bec... read more here.
Keywords: therapy; renal function; cisplatin plus; association renal ... See more keywords
Initial experience of preoperative gemcitabine and cisplatin plus durvalumab followed by resection for high-risk biliary tract cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e16329
Abstract: e16329 Background: Althoughgemcitabine and cisplatin plus durvalumab (GC+D) are standard of care for metastatic biliary tract cancer (BTC), the regimen’s effectiveness in the neoadjuvant setting for resectable disease remains unkown. We sought to evaluate early… read more here.
Keywords: plus durvalumab; resection; high risk; biliary tract ... See more keywords
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.02544
Abstract: PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS… read more here.
Keywords: oncology; cell; cisplatin pemetrexed; phase ... See more keywords
Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of thoracic disease"
DOI: 10.21037/jtd-20-1493
Abstract: Background Primary lung cancer with severe central airway obstruction (CAO) is often life-threatening. In this study, we investigated the clinical efficacy and safety of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection in treatment of… read more here.
Keywords: endostatin intratumoral; intratumoral injection; injection; airway ... See more keywords
Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15680
Abstract: Background/Aim: This phase II study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1. Patients and Methods: This single-arm, open-label, multicenter, phase II study was conducted by… read more here.
Keywords: cancer; phase; cisplatin plus; capecitabine ... See more keywords
HAEMATOLOGICAL TOXICITIES OF GEMCITABINE PLUS CISPLATIN VERSUS FLUOROURACIL, CISPLATIN, PLUS DOCETAXEL FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Ayub Medical College, Abbottabad : JAMC"
DOI: 10.55519/jamc-01-12489
Abstract: Background Nasopharyngeal carcinoma is endowed with unique epidemiological characteristics, treatment modalities, and prognostic considerations. Patients with bulky primary tumours and extensive nodal involvement are categorized as locoregionally advanced NPC. These patients present a high-risk cohort… read more here.
Keywords: gemcitabine plus; group; nasopharyngeal carcinoma; cisplatin plus ... See more keywords